AN Venture Partners (ANV), a global biotech venture capital fund, announced the promotion of Paula Schultheiss to Senior Associate, effective immediately.
Paula joined ANV as a full-time Associate in June 2025, having spent a year serving the firm as a Fellow during her doctoral research. Since then, she has made significant contributions to ANV's investment and company creation activities. She serves as a Board Observer at Typewriter Therapeutics and was instrumental in ANV's recent investment into Tortugas Neurosciences.
"Her promotion reflects the impact she has already made across our portfolio and our company creation activities. We look forward to her continued contributions as we advance our mission of bringing breakthrough science to the world." said Ken Horne, Managing Partner.
Paula has a multidisciplinary background in immunology, mechanobiology, and computational biology. She earned her Ph.D. in Biomedical Engineering from Columbia University, where her research focused on how mechanical cues shape T cell differentiation and function in solid tumors.
Prior to joining ANV full-time, Paula gained experience in biotech investing at Orange Grove Bio and Columbia Technology Ventures, where she evaluated the translational and commercial potential of academic discoveries across disciplines.
Paula said: “I am grateful for the trust ANV has placed in me through this promotion. Working alongside this team and seeing firsthand the impact that thoughtful, science-driven investing can have has been enormously rewarding. ANV's mission of translating cutting-edge Japanese science into globally impactful therapies is one I feel privileged to be part of. I am excited to take on greater responsibility as we continue to grow the portfolio."
